The first 48 hours after your injection

Walking out of the clinic, most patients notice a dull ache and a sense of fullness or pressure inside the treated knee. Both are normal. Because ChondroFiller is delivered as an ultrasound-guided outpatient injection — no incision, no general anaesthetic, no wound dressing — there is nothing to clean or dress when you get home; the collagen gel has already formed in situ within minutes of the procedure.

The soreness typically peaks within the first few hours and settles on its own within 24–48 hours, reflecting the scaffold settling into the defect rather than signalling a complication. Mild swelling and a degree of stiffness over the first two to three days are also expected parts of the early healing response.

Pain relief. Paracetamol is the first-line option and is appropriate for most patients during this window. Ibuprofen and other NSAIDs can reduce inflammation, but they should be used cautiously: anti-inflammatory medicines may interfere with the biological environment the scaffold needs in order to recruit the body's own repair cells. If you are considering an NSAID, check with your treating clinician first.

Practical points for the first day. Driving is restricted for at least 24 hours after the injection — longer if it was your right knee or you drive a manual vehicle. Keeping the knee elevated when sitting, and applying an ice pack wrapped in a cloth for short intervals, can help manage early swelling. Light activity around the home from the evening of the procedure is appropriate; heavy loading of the joint is not.

Weeks 1–6: protecting the scaffold

The six weeks that follow the injection are often described as the Protect phase, and the name is deliberate. The collagen scaffold has bonded to the fibrin environment inside the joint almost immediately, but the critical repair process — acellular matrix-induced chondrogenesis — takes considerably longer. In plain terms: the scaffold is in place, but your body's own progenitor cells now need several weeks to migrate into it and begin laying down new tissue. That migration is vulnerable to disruption by compressive and shear forces through the joint, which is why loading restrictions during this window are a clinical priority rather than an excess of caution.

Crutches are commonly recommended throughout this phase; the non-weight-bearing or partial weight-bearing period typically runs four to six weeks. In the first fortnight especially, sustained standing, stair-climbing, and carrying load through the knee should be avoided — think of it as giving the scaffold a stable environment to work with while the repair cells move in.

What the Protect phase is not is a period of total rest. Gentle, controlled range-of-motion exercises are actively encouraged from the outset to prevent the joint from stiffening. The goal is purposeful, low-load movement rather than stillness.

Exact exercise prescription — which movements, how often, and at what intensity — should come from your treating physiotherapist, who will tailor the programme to the size of your defect and your baseline strength.

Weeks 6–12: rebuilding strength around the knee

The six-week clinical review is the pivot point of the whole recovery. At that appointment, a clinician assesses whether the scaffold has stabilised sufficiently to tolerate progressive loading — and it is that assessment, not the calendar date alone, that gates the move into structured physiotherapy. For most patients the transition happens around week six, but individual tissue response and defect size mean the exact timing varies.

Once that progression is confirmed, rehabilitation shifts its focus to the muscle groups that protect the knee joint from excessive compressive force: the quadriceps at the front of the thigh, the hamstrings behind it, and the gluteal muscles of the hip and pelvis. Strengthening these three groups matters because well-conditioned surrounding musculature absorbs and distributes load through the joint, reducing the mechanical demands placed on the still-maturing scaffold beneath the articular surface.

Compressive loading is reintroduced gradually across this phase as the scaffold continues to integrate, with the rate of progression guided by how the knee is responding rather than by a fixed timetable. Many patients notice that stiffness — a feature of the earlier weeks — begins to ease during this period, and early functional gains in walking comfort and confidence on stairs are commonly reported.

The specific movements, intensity, and rate of progression should be set by the treating physiotherapist in light of individual progress; there is no single universal prescription that applies across all defect sizes and starting points.

Months 3 to 12: returning to activity

Around month three, most patients begin to notice genuine, if incremental, change — reduced aching on longer walks, greater confidence on stairs, or waking without the background stiffness that dominated the earlier weeks. The improvement rarely arrives as a clear before-and-after moment; it accumulates gradually as tissue remodelling progresses, and many patients only recognise how far they have come by looking back rather than forward.

Between months three and six, a progressive return to full daily activities and light sport is typical for suitable patients, guided by how the knee is responding to loading rather than by a fixed calendar milestone. The regenerating tissue is still maturing throughout this period, so avoiding sudden spikes in impact — and maintaining a healthy weight — supports the process rather than simply accelerating it.

High-impact activities such as running, jumping, and heavy lifting are typically deferred to around twelve months. The reason is biological rather than arbitrary: the collagen scaffold is biodegradable, gradually resorbing and being replaced by the patient's own tissue over 12–24 months. Until that remodelling cycle is substantially complete, the repair tissue has not yet reached the mechanical durability of established cartilage, and premature loading risks compromising it.

There is no single point in the calendar at which recovery ends. Benefits tend to consolidate across the first year rather than plateau early, and ongoing loading management remains relevant even once day-to-day symptoms have largely resolved.

What outcomes the evidence supports

Post-treatment MRI findings add a structural dimension to the outcome picture. In published follow-up studies, patients show reduction in bone marrow oedema (abnormal fluid signal within the bone immediately beneath the cartilage surface), diminished periarticular effusion (fluid pooling around the joint), and visible widening of the joint space — indicators that point to genuine tissue-level change rather than symptomatic masking alone.

The 70–85% rate of significant symptom relief, cited consistently across clinic-level outcome series, means that roughly one in five to three patients does not achieve meaningful improvement. That proportion matters when weighing options, and it reflects real variation: defect size, location within the joint, and how closely the rehabilitation protocol is followed are the principal factors on the patient side. Results reported for focal Grade III/IV defects cannot be extrapolated to patients with widespread osteoarthritis, for whom ChondroFiller is not indicated.

The evidence base is real but moderate in volume. Most published data derives from observational series or manufacturer-associated studies; large independent randomised controlled trials directly comparing ChondroFiller with alternative cartilage repair strategies remain limited. That gap does not invalidate the existing findings — the structural MRI data and reported symptom outcomes are consistent across sources — but it does mean that individual suitability, realistic expectations, and defect-specific factors are best established through a consultant assessment rather than benchmarked solely against population-level figures.

Factors that shape your individual recovery

Recovery from a ChondroFiller injection is not a passive process — the patient's own behaviour shapes the result in ways that population-level success rates cannot fully capture.

Rehabilitation adherence remains the single most modifiable variable. Following the phased protocol consistently — limiting loading in weeks 1–6, progressing through structured strengthening from week 6, and resisting the temptation to return to high-impact activity ahead of schedule — is precisely what the available outcome data reflects. Patients who deviate from the timeline risk disrupting the maturing repair tissue at the point when it is most vulnerable.

Defect size and depth set the biological ceiling. Larger or deeper focal lesions require a greater volume of scaffold and a longer remodelling period; smaller, well-bounded defects tend to respond more quickly and more completely.

Knee loading between sessions matters beyond formal exercise. Maintaining a healthy body weight and avoiding unplanned impact — a missed step, premature return to sport — protects the repair zone continuously, not only during supervised appointments.

Red flags warranting prompt clinical review include a sudden, marked increase in joint swelling, sharp mechanical pain that differs clearly in character from post-procedure soreness, or any fever developing in the days after the injection. These presentations are uncommon but should not be self-managed at home.

Ultimately, patients who understand the biology behind each phase — and act accordingly — give the scaffold the conditions it needs to do its work.

About Lincolnshire Knee

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without referral. Book an assessment at lincolnshireknee.co.uk.